Download PDF
Thromb Haemost 2007; 97(03): 464-470
DOI: 10.1160/TH06-09-0523
Cellular Proteolysis and Oncology
Schattauer GmbH

Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers

Florian Langer
1   II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
,
Felix Kyoung-Hwan Chun
2   Klinik und Poliklinik für Urologie, Universitätsklinikum Eppendorf, Hamburg, Germany
,
Ali Amirkhosravi
3   Florida Hospital Institute of Translational Research, Orlando, Florida, USA
,
Martin Friedrich
2   Klinik und Poliklinik für Urologie, Universitätsklinikum Eppendorf, Hamburg, Germany
,
Sven Leuenroth
4   Institut für Pathologie, Universitätsklinikum Eppendorf, Hamburg, Germany
,
Barbara Eifrig
1   II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
,
Carsten Bokemeyer
1   II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
,
John L. Francis
3   Florida Hospital Institute of Translational Research, Orlando, Florida, USA
› Author Affiliations
Further Information

Publication History

Received 15 September 2006

Accepted after resubmission 22 February 2006

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

Tissue factor (TF) is involved in cancer growth and metastasis, and haemostatic abnormalities are found in most patients with advanced malignancies, including prostate cancer (PC). Because anti-haemostatic agents are increasingly screened for their potential to prolong survival in tumor patients, a detailed characterization of haemostatic markers in selected cancer subtypes and clinical stages is warranted. In this study, we measured preoperative plasma TF antigen in a large cohort of patients with localized PC and correlated its levels with markers of coagulation and platelet activation, prostate-specific antigen (PSA), and his-topathological findings to explore its potential as a prognostic marker in this tumor entity. Out of 140 patients, 19% and 23% had plasma TF antigen levels of <40 pg/ml (low-TF) and >200 pg/ ml (high-TF), respectively, which was substantially higher than in 42 healthy male controls. Patients also had low-grade systemic coagulation activation as evidenced by elevated D-dimer, FI +2, and PAP plasma levels. Furthermore, similar to sP-selectin and sCD40L antigen, flow cytometric analysis of platelet-derived microparticles in plasma revealed significantly increased numbers in high-TF as compared to low-TF patients and controls. Whereas elevated D-dimer was associated with larger and less differentiated tumors, preoperative plasmaTF antigen levels (median [IQR]) were higher in patients with (161 pg/ml [100-236]) than in those without recurrent PC (105 pg/ml [52-182]), as indicated by a serum PSA of >0.1 ng/ml during ambulatory follow-up. In patients with localized PC, preoperative plasma TF antigen levels correlate with platelet activation in vivo and may indicate an increased risk for recurrent disease.

Keywords

Tissue factor/factor VII - cancer - microparticles

Footnote: Parts of this work were presented at the 47th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, USA 2005.


 

  • References

  • 1 Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-1022.
    CrossrefPubMedSearch in Google Scholar
  • 2 Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25: 1545-1550.
    CrossrefPubMedSearch in Google Scholar
  • 3 Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32: 61-68.
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Kakkar AK, Lemoine NR, Scully MF. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-1104.
    CrossrefPubMedSearch in Google Scholar
  • 5 Shigemori C, Wada H, Matsumoto K. et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80: 894-898.
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998; 79: 19-22.
    CrossrefPubMedSearch in Google Scholar
  • 7 Abdulkadir SA, Carvalhal GF, Kaleem Z. et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31: 443-447.
    CrossrefPubMedSearch in Google Scholar
  • 8 Ohta S, Wada H, Nakazaki T. et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22: 2991-2996.
    PubMedSearch in Google Scholar
  • 9 Seitz R, Rappe N, Kraus M. et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 1993; 4: 249-254.
    CrossrefPubMedSearch in Google Scholar
  • 10 Oya M, Akiyama Y, Okuyama T. et al. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001; 31: 388-394.
    CrossrefPubMedSearch in Google Scholar
  • 11 Dirix LY, Salgado R, Weytjens R. et al. Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395.
    CrossrefPubMedSearch in Google Scholar
  • 12 Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97: 3044-3052.
    CrossrefPubMedSearch in Google Scholar
  • 13 Lind SE, Caprini JA, Goldshteyn S. et al. Correlates of thrombin generation in patients with advanced prostate cancer. Thromb Haemost 2003; 89: 185-189.
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Bogdanov VY, Balasubramanian V, Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-462.
    CrossrefPubMedSearch in Google Scholar
  • 15 Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23.
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Parhami-Seren B, Butenas S, Krudysz-Amblo J. et al. Immunologic quantitation of tissue factor. J Thromb Haemost 2006; 4: 1747-1755.
    CrossrefPubMedSearch in Google Scholar
  • 17 Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus. Circulation 2004; 109: 2524-2528.
    CrossrefPubMedSearch in Google Scholar
  • 18 Sase T, Wada H, Kamikura Y. et al. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb Haemost 2004; 92: 132-139.
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Mohan JS, Lip GYH, Wright J. et al. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood Coagul Fibrinolysis 2005; 16: 209-214.
    CrossrefPubMedSearch in Google Scholar
  • 20 Kim HK, Song KS, Park YS. et al. Changes of plasma tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 2000; 93: 31-36.
    CrossrefPubMedSearch in Google Scholar
  • 21 Han LY, Landen Jr CN, Kamat AA. et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006; 24: 755-761.
    CrossrefPubMedSearch in Google Scholar
  • 22 Kohli M, Fink LM, Spencer HJ. et al. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002; 13: 1-5.
    CrossrefPubMedSearch in Google Scholar
  • 23 Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Haemost 2003; 29: 301-308.
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 de la Fouchardière C, Flechon A, Droz JP. Coagulopathy in prostate cancer. Neth J Med 2003; 61: 347-354.
    PubMedSearch in Google Scholar
  • 25 Bill-Axelson A, Holmberg L, Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984.
    CrossrefPubMedSearch in Google Scholar
  • 26 Kakkar AK, Levine MN, Kadziola Z. et al. Low molecular weight heparin, therapy with Dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
    CrossrefPubMedSearch in Google Scholar
  • 27 Lee AY, Rickles FR, Julian JA. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
    CrossrefPubMedSearch in Google Scholar
  • 28 Combes V, Dignat-George F, Mutin M. et al. A new flow cytometry method of platelet-derived microvesicle quantitation in plasma. Thromb Haemost 1997; 77: 220
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Roselli M, Mineo TC, Basili S. et al. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res 2004; 10: 610-614.
    CrossrefPubMedSearch in Google Scholar
  • 30 Caine JC, Lip GYH, Stonelake PSS. et al. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004; 92: 185-190.
    Thieme ConnectPubMedSearch in Google Scholar
  • 31 Butenas S, Bouchard BA, Brummel-Ziedins KE. et al. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770.
    CrossrefPubMedSearch in Google Scholar
  • 32 Fink L, Holschermann H, Kwapiszewska G. et al. Characterization of platelet-specific mRNA by realtime PCR after laser-assisted microdissection. Thromb Haemost. 2003: 749-756.
    PubMedSearch in Google Scholar
  • 33 Camera M, Frigerio M, Toschi V. et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol 2003; 23: 1690-1696.
    CrossrefPubMedSearch in Google Scholar
  • 34 Siddiqui FA, Desai H, Amirkhosravi A. et al. The presence and release of tissue factor from human platelets. Platelets 2002; 13: 247-253.
    CrossrefPubMedSearch in Google Scholar
  • 35 Muller I, Klocke A, Alex M. et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-478.
    CrossrefPubMedSearch in Google Scholar
  • 36 Osterud B. The role of platelets in decrypting monocyte tissue factor. Semin Hematol 2001; 38: 2-5.
    PubMedSearch in Google Scholar
  • 37 Del Conde I, Shrimpton CN, Thiagarajan P. et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
    CrossrefPubMedSearch in Google Scholar
  • 38 Nakashima J, Tachibana M, Ueno M. et al. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res 1995; 55: 4881-4885.
    PubMedSearch in Google Scholar
  • 39 Schwertz H, Tolley ND, Foulks JM. et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets. J Exp Med 2006; 203: 2433-2440.
    CrossrefPubMedSearch in Google Scholar
  • 40 Akashi T, Furuya Y, Ohta S. et al. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003; 62: 1078-1082.
    CrossrefPubMedSearch in Google Scholar